Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
Janux Therapeutics reported Q1 financials featuring a $35 million milestone payment from Bristol Myers Squibb following a development candidate nomination, boosting cash reserves to $956.4 million. On the clinical front, JANX007 continues enrolling in Phase 1b, and JANX014 has initiated evaluation, while JANX008 was discontinued after Phase 1a.
Key figures
- Revenue
- 3733000
- Net loss
- 24361000
- Rd expenses
- 26813000
- Cash position
- 956400000
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.